An interventional study of TROD in Respiratory Infections and Antibiotic, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Respiratory Tract Infections with a site in France — 18 open to participants now, 18 under way, 4 of them phase 3. Respiratory Tract Infections · France.
Among the 49 studies in Respiratory Tract Infections with a site in France, this one is the 4th largest by planned enrollment of the 32 interventional ones that give a count, is one of 12 that started in 2026, is one of 18 with no phase, reaches primary completion later than 6 of the 17 other live ones, and was the 38th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.
Browse Respiratory Tract Infections studies →18 of the 49 studies in Respiratory Tract Infections with a site in France are open now. Recruiting first, the newest first:
Givaudan France Naturals · Sites in France
Ages 18–65 · Healthy volunteers
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Centre Hospitalier Annecy Genevois · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Grenoble · Sites in France, United States, Germany and 2 more countries
Ages 60+
University Hospital, Caen · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 301 across the 32 interventional studies, 124 across the 17 observational. Of the 29 that completed or were terminated, 5 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 49 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 7 studies filed under Respiratory Tract Infections — fewer than ten, so there is no comparison to draw.
7 of the studies in Respiratory Tract Infections with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06197152Assistance Publique - Hôpitaux de ParisIdentification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV | 2026-12 |
| NCT07787130Givaudan France NaturalsEffect of Immune X on Common Cold Incidence in Healthy Adults | 2027-03-01 |
| NCT07625683Laboratoires ElerteObservational Study of SIROPSEDAL in Acute Cough | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 49 studies in Respiratory Tract Infections with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Respiratory infections are very common, especially during winter, and are often caused by viruses such as influenza, SARS-CoV-2 or respiratory syncytial virus (RSV).
These illnesses are generally mild, but their symptoms do not always allow a clear distinction to be made between a viral infection and a bacterial infection. In the absence of a precise diagnosis, antibiotics may be prescribed when they are not necessary in many cases.
However, the excessive use of antibiotics contributes to the development of bacterial resistance, which is a major public health issue.
The aim of this study is to better understand whether the use of a rapid test (called TROD), which can quickly identify certain respiratory viruses, can help doctors reduce unnecessary antibiotic prescriptions for these infections. The test will be performed using a swab gently inserted into the nose.
Bacterial resistance to antibiotics is a major global public health issue. In France, this resistance is estimated to cause 158,000 infections annually (127,000 to 245,000), including nearly 16,000 invasive infections, and 12,500 deaths per year. The additional cost of antibiotics in France compared to the average for the most virtuous European countries has been estimated at €441 million.
Reducing exposure to antibiotics by limiting their prescription to situations where they are essential is one of the major levers for slowing down the emergence of resistance.
The vast majority of antibiotics are prescribed in outpatient settings (90% of consumption, or 125 million units per year). In France, respiratory tract infections account for 7 out of 10 prescriptions in primary care. However, the majority of respiratory infections are viral in origin (influenza viruses, respiratory syncytial virus (RSV), SARS-CoV-2, but also rhinoviruses, metapneumoviruses, etc.). The clinical presentation of these infections is often non-specific. The lack of microbiological aetiological diagnosis leads to the unnecessary prescription of antibiotics in many cases of viral infections.
The rapid diagnostic tests (TROD) that have recently become available can test for RSV, influenza viruses and SARS-CoV-2 simultaneously. They enable a diagnosis of viral infection to be made during a consultation and should help to avoid the prescription of antibiotics in these situations. In addition, these tests are simple and can be performed routinely (in less than 15 minutes) without the need for specific equipment or technical skills. Reducing inappropriate prescriptions of antibiotic treatments for viral respiratory infections is therefore a public health priority that is likely to have a significant impact on bacterial resistance, but also on the incidence of adverse effects and the costs associated with these treatments.
At the request of the Haute Autorité de Santé (French National Authority for Health), this study aims to estimate the impact of triplex TRODs (SARS-CoV-2/ influenza/RSV detection) on antibiotic prescriptions in the general population in community settings among patients with infectious syndrome, and to produce data (comparative to RT-PCR) to better estimate the diagnostic performance, sensitivity and specificity of the test used in the study.
The participation period for each participating doctor will be determined by random draw, with the aim of ensuring that the start dates of participation are spread throughout the study period, and with each doctor having a first control period without the use of tests (n = 10 patients) followed by a second period with the use of tests (n = 10 patients). Antibiotic prescriptions will be collected for each patient included during the two periods.
Each investigator will begin the study (on the randomly selected date) by including 10 patients who meet the eligibility criteria during the period without testing (first period), then the investigating physician will move on to the second period and use the TROD for 10 other patients.
The main objective is to evaluate the impact of using triplex rapid diagnostic tests (SARS-CoV-2/influenza/RSV) on antibiotic prescribing in the general population in community settings during the autumn-winter season of 2025-2026.
The secondary objectives are to : 1. Compare the probability of prescription during the initial consultation between the two study periods, 2. Compare the frequency of patient re-consultations within 15 days of inclusion between the two study periods, 3. Compare the proportions of patients with secondary hospitalisation within 15 days of inclusion between the two study periods, 4. Compare total antibiotic consumption within 15 days of inclusion between the two study periods, 5. Conduct a cost-consequence medical-economic study, 6. Assess the impact of these tests according to patient characteristics (age, medical history, initial symptoms, etc.) and prescribers (age, geographical area, practice modalities.), 7. Assess the proportions of SARS-CoV-2/influenza/RSV during the intervention period in patients presenting with all of the described symptoms of respiratory infection, 8. Estimate the sensitivity and specificity of the TROD in identifying different viruses using respiratory multiplex PCR, as well as the frequency and nature of other respiratory viral infections, 9. Describe the epidemiology of other respiratory viral infections, whether or not associated with SARS-CoV-2/influenza/RSV infections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presenting with:
Either fever (temperature > 38°C measured by patient or physician) within the past 72 hours, and one of the following symptom combinations:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients without triplex TROD tests. Doctors may or may not prescribe antibiotics probabilistically as usual.
Patient with triplex TROD test. Doctors may or may not prescribe antibiotics with the help of the results of triplex TROD tests.
Diagnostic Test: TROD
Patient with triplex TROD test. Doctors may or may not prescribe antibiotics with the help of the results of triplex TROD tests.
Variation in the probability of antibiotic prescription between adjacent periods differing in the use of tests TROD
Variation in antibiotic prescription rate between 1st periods during which doctors prescribe antibiotics probabilistically without rapid diagnostic tests (TROD) as usual, followed by 2nd periods during which antibiotic prescription is guided by the results of triple TROD (SARS-CoV-2/influenza/RSV). The primary endpoint will take into account all antibiotic prescriptions received by patients within 15 days of inclusion, whether they were prescribed at the end of the consultation that led to inclusion or during follow-up consultations.
Time frame: Day 0 to Day 14
Percentage of patients receiving an antibiotic prescription at the initial consultation in both groups
Time frame: Day 0
Percentage of patients requiring a new medical consultation between inclusion and day 14 in both groups
Time frame: Day 0 to Day 14
Percentage of patients requiring secondary hospitalisation between inclusion and day 14 in both groups
Time frame: Day 0 to Day 14
Total antibiotic consumption on day 14 in both groups
Time frame: Day 0 to Day 14
Total cost of patient care
Cost-consequence medical-economic study
Time frame: Day 0 to Day 14
Previous criteria 2-4 according to patient characteristics and prescribers
Time frame: Day 0 to Day 14
Percentage of patients with positive TROD results for the viruses studied during the intervention period (PCR and TROD)
Time frame: Day 0 to Day 14
Estimation of the sensitivities and specificities of the TROD with regard to different viruses
TROD compared to the identification of different viruses using respiratory multiplex PCR in approximately 750 patients
Time frame: Day 0
Frequency of other respiratory viral infections associated or not associated with SARS-CoV-2/influenza/Respiratory syncytial virus infections
Epidemiology of other respiratory viral infections associated or not associated with SARS-CoV-2/influenza/RSV among Influenza A, Influenza B, Respiratory syncytial virus, SARS-CoV-2, Adenovirus B/E, Adenovirus C, Metapneumovirus, Enterovirus/rhinovirus, Coronavirus OC43, Coronavirus HKU1, Coronavirus 229E, Coronavirus NL63, Human parainfluenza virus 1 to 4.
Time frame: Day 0
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.
Of 119 non-industry interventional studies with no phase under Respiratory Tract Infections, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 18 months is above that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Tract Infections →
Assistance Publique - Hôpitaux de Paris →